吉西他滨联合卡铂治疗晚期NSCLC的临床观察  

Effect analysis of gemcitabine compared with carboplatin for the treatment in advanced non-small cell lung cancer

作　　者：智玲玲[1] 王洪海[1] 李志英[1] 

机构地区：[1]安阳市肿瘤医院化疗科,河南安阳455000

出　　处：《中华肿瘤防治杂志》2012年第20期1566-1568,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨吉西他滨联合卡铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将98例晚期NSCLC患者随机分入A组(吉西他滨联合卡铂)和B组(吉西他滨联合顺铂),A组给予吉西他滨1 000mg/m2,d1～d2,静脉滴入,卡铂根据曲线下面积=5给药,d1,静脉滴入;B组在吉西他滨给药的同时,给予顺铂80mg/m2,d1～d2,静脉滴入。21d为1个周期,至少治疗2个周期。比较两组治疗有效率、1年生存率、不良反应发生率及生活质量。结果:A组有效率(CR+PR)为39.7%(23/58),B组CR+PR 40.0%(16/40);A组与B组1年生存率分别为52.1%和45.0%,两组有效率及1年生存率均差异无统计学意义,P>0.05;A组无Ⅲ+Ⅳ度胃肠道反应,显著少于B组的12.5%,P<0.05;治疗后A组LCSS量表评分显著优于B组,P<0.05。结论:吉西他滨联合卡铂或顺铂治疗晚期NSCLC同等有效,但前者不良反应少,患者耐受性好,生活质量高。OBJECTIVE： To explore the clinical effect of gemcitabine compared with carboplatin treatment in ad- vanced non-small cell lung cancer. METHODS： Totally 98 cases with advanced non-small cell lung cancer were randomly divided into group A （gemcitabine compared with carboplatin） and group B （gemcitabine compared with cisplatin）. Group A received gemcitabine of 1 000 mg/m2 on day 1 and 8,and carboplatin of AUC 5 on day 1. Group B were given cisplatin 80 mg/mz on dl and 2 based on gemcitabine treatment. Twenty-one days were for a cycle and all the patients received 2 cy cles of treatments. Effective rate of treatment, 1 year survival rate, adverse reaction rate and life quantity were compared between two groups. RESULTS： Effective rates of treatment were 39.7% and 40.0% in group A and group B respectively （P〉0.05）; There were no significant difference of 1 year survival rate between two groups （52.1%ros 45.0%, P〉 0.05）; Grade Ⅲ ～ IV gastrointestinal effect in group A were much less than that in group B（0 vs 12. 5%, P〈0.05）; LCSS scores after treatment in group A were superior to group B （P〈0.05）. CONCLUSIONS： Gemcitabine compared with carboplatin or cisplatin treatment in advanced non-small cell lung cancer achieve the same effectiveness. Gemcitahine compared with carboplatin have less adverse reaction rate,and it is well-tolerated for patients.

关 键 词：癌 非小细胞肺 卡铂 投药和剂量 输注 静脉内 脱氧胞苷 类似物和衍生物 

分 类 号：R734.2[医药卫生—肿瘤]